CY1122442T1 - Μεθοδοι για την αγωγη ηπατιτιδας c - Google Patents

Μεθοδοι για την αγωγη ηπατιτιδας c

Info

Publication number
CY1122442T1
CY1122442T1 CY20191101109T CY191101109T CY1122442T1 CY 1122442 T1 CY1122442 T1 CY 1122442T1 CY 20191101109 T CY20191101109 T CY 20191101109T CY 191101109 T CY191101109 T CY 191101109T CY 1122442 T1 CY1122442 T1 CY 1122442T1
Authority
CY
Cyprus
Prior art keywords
methods
inducing hepatitis
hepatitis
inducing
inhibitors
Prior art date
Application number
CY20191101109T
Other languages
English (en)
Inventor
Teresa Ng (Iok-Chan)
Tami J. Pilot-Matias
Warren M. Kati
Preethi Krishnan
Clarence J. Maring
Neeta C. Mistry
Thomas J. REISCH
Rolf Wagner
Dachun Liu
John K. Pratt
Mark A. Matulenko
Ryan G. Keddy
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122442(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1122442T1 publication Critical patent/CY1122442T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Περιγράφονται παν-γονοτυπικοί αναστολείς HCV. Η παρούσα εφεύρεση αφορά επίσης μεθόδους χρήσης αυτών των αναστολέων στην αγωγή μόλυνσης HCV.
CY20191101109T 2012-09-18 2019-10-24 Μεθοδοι για την αγωγη ηπατιτιδας c CY1122442T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
CY1122442T1 true CY1122442T1 (el) 2021-01-27

Family

ID=49304326

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101109T CY1122442T1 (el) 2012-09-18 2019-10-24 Μεθοδοι για την αγωγη ηπατιτιδας c

Country Status (25)

Country Link
US (1) US20140080868A1 (el)
EP (2) EP2897611B1 (el)
JP (4) JP6297044B2 (el)
CN (1) CN104797253A (el)
AU (2) AU2013318302B2 (el)
BR (1) BR112015006037B1 (el)
CA (1) CA2884539C (el)
CY (1) CY1122442T1 (el)
DK (1) DK2897611T3 (el)
ES (1) ES2755089T3 (el)
HK (1) HK1209319A1 (el)
HR (1) HRP20191939T1 (el)
HU (1) HUE046544T2 (el)
LT (1) LT2897611T (el)
MX (2) MX367796B (el)
NZ (1) NZ630581A (el)
PL (1) PL2897611T3 (el)
PT (1) PT2897611T (el)
RS (1) RS59640B1 (el)
RU (1) RU2665365C2 (el)
SG (2) SG11201502095SA (el)
SI (1) SI2897611T1 (el)
TW (1) TWI621436B (el)
WO (1) WO2014047039A1 (el)
ZA (1) ZA201501752B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
LT2968301T (lt) * 2013-03-14 2017-05-25 Abbvie Inc. Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
MX2016012799A (es) 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
EP3313378A1 (en) * 2015-06-26 2018-05-02 AbbVie Inc. Solid pharmaceutical compositions for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Hcvを処置するための方法
AU2016296709C1 (en) * 2015-07-17 2022-02-24 Abbvie Inc. Solid pharmaceutical compositions for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092616A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c

Also Published As

Publication number Publication date
ZA201501752B (en) 2016-08-31
EP2897611A1 (en) 2015-07-29
LT2897611T (lt) 2019-12-10
DK2897611T3 (da) 2019-11-04
CN104797253A (zh) 2015-07-22
NZ630581A (en) 2017-02-24
SI2897611T1 (sl) 2019-12-31
HK1209319A1 (en) 2016-04-01
PL2897611T3 (pl) 2020-03-31
CA2884539A1 (en) 2014-03-27
TW201412311A (zh) 2014-04-01
RS59640B1 (sr) 2020-01-31
HUE046544T2 (hu) 2020-03-30
AU2018203608B2 (en) 2019-12-19
JP6556884B2 (ja) 2019-08-07
JP2018109035A (ja) 2018-07-12
ES2755089T3 (es) 2020-04-21
EP2897611B1 (en) 2019-07-24
AU2018203608A1 (en) 2018-06-14
JP6297044B2 (ja) 2018-03-20
BR112015006037A2 (pt) 2017-07-04
BR112015006037B1 (pt) 2022-05-17
SG10201702248UA (en) 2017-04-27
MX367796B (es) 2019-09-06
JP2019194241A (ja) 2019-11-07
AU2013318302B2 (en) 2018-02-22
PT2897611T (pt) 2019-11-27
MX2015003501A (es) 2015-10-26
HRP20191939T1 (hr) 2020-01-10
AU2013318302A1 (en) 2015-04-02
WO2014047039A1 (en) 2014-03-27
MX2019010600A (es) 2020-02-03
EP3597190A1 (en) 2020-01-22
SG11201502095SA (en) 2015-05-28
JP2015528511A (ja) 2015-09-28
RU2665365C2 (ru) 2018-08-29
US20140080868A1 (en) 2014-03-20
TWI621436B (zh) 2018-04-21
JP2021054849A (ja) 2021-04-08
CA2884539C (en) 2022-06-21
RU2015114543A (ru) 2016-11-10

Similar Documents

Publication Publication Date Title
CY1122442T1 (el) Μεθοδοι για την αγωγη ηπατιτιδας c
CY1124469T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201790630A1 (ru) Способы получения рибозидов
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CY1118567T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
CR20130424A (es) Terapéuticos a base de levadura para infección de la hepatitis b crónica
DK3043865T3 (da) Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA201390133A1 (ru) Способы получения диастереомерно чистых фосфорамидатных пролекарств
EA201370017A1 (ru) Ингибиторы вируса гепатита с
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
UY34066A (es) Inhibidores del virus de la hepatitis c
EA201590770A1 (ru) Ингибиторы вируса гепатита с
BR112014013972A2 (pt) inibidores de hcv nssa
MX2016005393A (es) Metodos para tratar vhc.
EA201692534A1 (ru) Способы лечения гипотонии
AU2013318309A8 (en) Methods for treating hepatitis C
BR112015006058A2 (pt) métodos para tratamento de hcv